Abstract: A security revolving door assembly including a revolving door, a controlling unit and a LIDAR sensor. The LIDAR sensor is appropriately disposed in the top or canopy of the revolving door and advantageously directed downwardly into the passage space of the revolving door. In particular, a first LIDAR sensor is centrally disposed in a first quadrant of the canopy, and a second LIDAR sensor is centrally disposed in a third quadrant of the canopy.

Abstract: A protein hydrolysate obtained from at least one protein source from bluefish having (i) a degree of hydrolysis (DH) of at least 10%, (ii) at least 80% water-soluble protein with a molecular weight of less than 1000 Da, (iii) at least 0.3% phospholipids, and (iv) at least 0.5% DHA and EPA.

Abstract: Disclosed is a device for detecting at least one chemical species in a medium to be analyzed including a chemical sensor, the chemical sensor including: a substrate; a functionalized carrier intended for capturing and accumulating the chemical species and attached to a side of the substrate. The device also includes a unit for diffusion between the medium to be analysed and the functionalised carrier. The diffusion unit includes a vibration generating system connected to the chemical sensor in order to subject the chemical sensor to controlled vibrations.

Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.

Abstract: The present invention relates to compound of formula (I): wherein R is O—R3 or R1 and R2 are identical or different and are each independently H, (C1-C6)alkyl, —CO—(C1-C21)alkyl or —CO—(C11-C21)alkenyl group, provided that at least one of R1 or R2 is H or (C1-C6)alkyl, R3 is a —CO—(C11-C21)alkyl or —CO—(C11-C21)alkenyl group, or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof, for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

Abstract: The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.

Abstract: The present invention relates to a compound of the following formula (I) or to a salt, hydrate, or pharmaceutically acceptable solvate thereof, in which R is a monosaccharide or disaccharide residue. The hydroxyl functions of the monosaccharide or disaccharide residue are, independently, optionally substituted for a (C1-C6) alkyl or —C(O)NH—(C1-C6) alkyl group. The invention also relates to the method for preparing said compound, to a pharmaceutical composition containing same, and to the use thereof as a drug, particularly for cancer treatment.

Abstract: The present invention relates to combinations of polypeptides or of polynucleotides corresponding to a specific region of the N-terminal portion of the VAR2CSA protein of different parasitic families or lines of Plasmodium falciparum, and to their use in the prevention of pregnancy-associated malaria. The invention also relates to immunogenic compositions and to vaccines useful for preventing malaria in pregnant women.

Abstract: The present invention relates to pharmaceutical compositions comprising a mixture of a specific HIV antigen and a non-pathogenic living bacterium. Said specific HIV antigen comprises one or more epitopes from Gag and/or Pol proteins and is preferably under a particulate form. Said bacterium is preferably Lactobacillus plantarum. These compositions are useful for preventing and/or treating an HIV disease in humans.

Abstract: The oligonucleotide of sequence SEQ ID No.1: 5?-CTAGAGATCCCTCAGA-3?, and the complementary sequence thereof of sequence SEQ ID No.2: 5?-TCTGAGGGATCTCTAG-3? useful as probes to detect and quantify all HIV-1 circulating forms and their precursors SIVcpz/SIVgor.

Abstract: The present invention relates to the use of 4-phenylbutyric acid, or one of the salts thereof, for improving the resistance of plants to harmful biological organisms, in particular to bacteria, viruses and nematodes, and for inhibiting hypersensitive cell death induced by such harmful biological organisms. The present invention also relates to the use of 4-phenylbutyric acid, or one of the salts thereof, as an antimicrobial agent for preventing or treating plant diseases caused by phytopathogens.

Abstract: The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The invention also provides immunogenic compositions and vaccines that are useful for preventing malaria in pregnant women.

Abstract: The present invention provides a method for determining the amino acid polymorphisms of heavy gamma chain of immunoglobulins G by a proteomic approach. This method distinguishes the immunoglobulins of the mother and those of the newborn in a blood sample obtained during the first months of the child's life. The invention also relates to the use of this method in the early diagnosis of vertically transmitted diseases in the neonate. The invention also provides peptides distinctive of G3m and IGHG3 alleles, and a kit comprising said peptides.

Abstract: A unit for measuring the falling speed of particles in suspension in a fluid comprises a sealed container having an open compartment containing fluid, and a sealed compartment, and, in the sealed compartment, at least three electromagnetic radiation emitters distributed along a longitudinal axis of the open compartment and oriented according to a radiation axis crossing the open compartment at different heights along the longitudinal axis, an equal number of receivers distributed along the longitudinal axis, each receiver placed in the radiation axis of a corresponding emitter, and a system for acquiring data connected to the receivers which is used to obtain the falling speed of the particles and the change of same as a function of the height in the open compartment and as a function of time, said change quantifying the flocculation of the particles.

Abstract: Apparatus for physically analyzing soil includes a sample changer for receiving at least two soil-sample holders, and having an element for placing each sample holder and sample thereof in a measurement area, in turns, according to a cycle repeated over time, the apparatus including: elements for measuring the size of the samples; elements for measuring the potential of the samples containing water; and elements for measuring the weight of the samples, wherein all of the measuring elements are grouped together in the measurement area so as to be simultaneously used implemented for a given sample when the latter is placed in the measurement area. The shrinkage curve and water potential curve, obtained from the measurements, represent the change, over time, in the status of the water and structure of the soil sample during the drying thereof, and can be used to determine the hydrostructural characteristics of the soil.

Abstract: Methods and systems for operation of direct methanol fuel cell (DFMC) systems with enhanced flexibility within a wide range of electrical loads as well as no external load are provided. With these methods and systems, the fuel cell operates at low power in a non shut-down state in a fully controlled manner thus allowing the fuel cell to withstand frost conditions and to maintain optimal ancillary battery capacity.

Abstract: The invention relates to the use of a gene of the Argonaute family, a transcript of said gene or the ORF of said gene in order to produce plants that are completely or partially apomictic. The invention can be used to control apomixis in cultivated species having sexual reproduction.

Abstract: The present invention relates to a compound of the following formula (I) or to a salt, hydrate, or pharmaceutically acceptable solvate thereof, in which R is a monosaccharide or disaccharide residue. The hydroxyl functions of the monosaccharide or disaccharide residue are, independently, optionally substituted for a (C1-C6) alkyl or —C(O)NH—(C1-C6) alkyl group. The invention also relates to the method for preparing said compound, to a pharmaceutical composition containing same, and to the use thereof as a drug, particularly for cancer treatment.

Abstract: The invention relates to the use of genes which, in plants, encode proteins with a functional diversity in terms of silencing, comprising the selection of the gene with the level of effectiveness in order to construct a plant viral vector having the function of overexpressing or silencing particular genes.

Abstract: The present invention relates to acetylsalicylic acid or a salt thereof, at a concentration comprised between 200 and 4800 ?M, for use in the prevention and/or treatment of diabetic wounds.